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Background: Breast cancer is a heterogeneous disease for which prognosis and treatment strategies are largely
governed by the receptor status (estrogen, progesterone and Her2) of the tumor cells. Gene expression profiling of
whole breast tumors further stratifies breast cancer into several molecular subtypes which also co-segregate with
the receptor status of the tumor cells. We postulated that cancer associated fibroblasts (CAFs) within the tumor
stroma may exhibit subtype specific gene expression profiles and thus contribute to the biology of the disease in a
subtype specific manner. Several studies have reported gene expression profile differences between CAFs and
normal breast fibroblasts but in none of these studies were the results stratified based on tumor subtypes.
Methods: To address whether gene expression in breast cancer associated fibroblasts varies between breast cancer
subtypes, we compared the gene expression profiles of early passage primary CAFs isolated from twenty human
breast cancer samples representing three main subtypes; seven ER+, seven triple negative (TNBC) and six Her2+.
Results: We observed significant expression differences between CAFs derived from Her2+ breast cancer and CAFs
from TNBC and ER + cancers, particularly in pathways associated with cytoskeleton and integrin signaling. In the
case of Her2+ breast cancer, the signaling pathways found to be selectively up regulated in CAFs likely contribute
to the enhanced migration of breast cancer cells in transwell assays and may contribute to the unfavorable
prognosis of Her2+ breast cancer.
Conclusions: These data demonstrate that in addition to the distinct molecular profiles that characterize the
neoplastic cells, CAF gene expression is also differentially regulated in distinct subtypes of breast cancer.Background
Gene expression profiling of whole breast tumors has
stratified breast cancer into several molecular subtypes
that largely correlate with the expression status of three
receptors in the tumor cells, namely estrogen (ER), pro-
gesterone (PR), and Her2-neu (Her2) [1,2]. The most
common breast cancer subtype expresses either ER or
PR but lacks Her2 expression. Breast cancers that do not
express any of the 3 receptors, known as triple negative
breast cancer (TNBC), and those that express Her2
(Her2+) are less common, comprising approximately* Correspondence: Julia.tchou@uphs.upenn.edu
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reproduction in any medium, provided the or15% and 25% of all breast cancers respectively. Her2+
and TNBC have less favorable prognosis compared to
ER+ cancers [3,4]. How cancer cells acquire a specific
molecular phenotype is uncertain. It has been postulated
recently that the tumor stroma and the cancer cells may
co-evolve to support the selection or enrichment of a
specific cancer subtype [5].
Much of the earlier gene expression profile analyses
of breast cancer were performed using RNA extracted
from tumor samples comprised of at least 50% of
tumor cells, with the tumor stromal cells being a minor
but important component. As tumor cell survival and
tumor progression are dependent on the tumor micro-
environment, elucidating the symbiotic relationship be-
tween neoplastic cells and stromal cells is crucial to
further our understanding of the pathogenesis of theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Tchou et al. BMC Medical Genomics 2012, 5:39 Page 2 of 13
http://www.biomedcentral.com/1755-8794/5/39disease [5-8]. This interdependency is reinforced by the
recent identification of a stroma-derived gene signature
that correlates with prognosis suggesting that the tumor
stroma contributes significantly to the invasive and
metastatic potential of tumor cells [9]. A unique breast
cancer stroma signature has also been observed in
women of African American descent compared to
European American descent [10], while a stromal gene
signature has been reported to predict response to
chemotherapy [11]. These observations support the sug-
gestion that intrinsic heterogeneities between the tumor
stroma may correlate with patient-specific characteristics,
prognosis, therapeutic response, and, perhaps, tumor sub-
types. However, breast cancer subtype-specific differences
have not yet been reported for the tumor stromal cells
even though multiple studies have shown that the gene
expression profiles of breast cancer associated fibroblasts
(CAFs) are distinctly different from their normal counter-
parts. None of these prior studies had stratified their
results based on tumor subtypes [12-16].
In this study, we isolated CAFs from twenty primary
breast cancer samples representing three main sub-
types (ER + (n = 7), TNBC (n = 7), Her2+ (n = 6)) and
performed gene expression profile analyses on RNA
isolated from these early passage CAFs. Subtype-
specific gene expression profile differences were
observed that distinguished CAFs derived from Her2+
cancers and TNBC and ER + cancers. Several genes,
e.g. ITGA3, ITGA5, CFL1, and RHOA, that were found to
be selectively up regulated in CAFs derived from Her2+
but not ER+or TNBC breast cancers are known to be
involved with pathways associated with integrin and RhoA
signaling suggesting that CAFs may contribute to the
invasiveness of Her2+ breast cancer [17]. Migration of
breast cancer cells,T47D, was significantly enhanced by
CAFs derived from Her2+ breast cancer compared
with ER + or TNBC. Our findings suggest that CAFs
might contribute to the biology of the disease in a
subtype-specific manner. Our findings are also con-
sistent with the recently proposed tumor-stroma co-
evolution hypothesis [5].
Methods
Patients and clinical characteristics of study cohort
Women with primary operable breast cancer undergoing
breast surgery at the Hospital of the University of Pennsyl-
vania were asked to participate in our tissue banking
protocol approved by the institutional review board.
Informed consent was obtained from all participants. Our
study cohort included 20 women diagnosed with breast
cancer between 2008 and 2011. Breast tumors were strati-
fied into three subgroups according to receptor expression
determined by immunohistochemistry (IHC) as described
previously [18]: 1) ER+denotes breast cancer whichexpresses either ER or PR and lacks Her2 expression
(n= 7); 2) TNBC denotes breast cancer that lacks expres-
sion of ER, PR, and Her2 (n= 7); and 3) Her2+ group
(n= 6) denotes breast cancer which expresses Her2
as determined by IHC and/or fluorescence in situ
hybridization with (n= 1) or without expression of ER or
PR (n= 5). All data collection and analyses were adherent
to Institutional Review Board approved protocols. Clinical
characteristics, including age at diagnosis, race, histology,
tumor size, tumor grade, and number of involved (+) ax-
illa nodes were compared. Pair-wise comparison was done
using two-tail t-test for age and tumor size, and Fisher’s
exact test for race (Caucasian vs. African-American), hist-
ology, tumor grade (II vs. III) and number of (+) axilla
nodes (none vs. one or more).Tissue dissociation and cell culture
After our surgical pathologists completed gross exam-
ination and inking of the tumor specimen, fresh tumor
tissue was taken from the center of the tumor without
interfering with margin assessment as determined by
the pathologists. The tissues were stored in ice cold
medium DMEM/F12 supplemented with 10% fetal bo-
vine serum (FBS), penicillin and streptomycin. The
fresh tumor tissue was kept on ice at 4°C until ready
for processing within 6 hours from the excision time.
If the tumor tissue weighed less than 0.5 gram (n = 5)
(TB160 – TB165), the tissue was mechanically disso-
ciated by mincing with scalpel and scissors to 1–2 mm3
in a 10 cm tissue culture plate. Fibroblast growth
medium (DMEM supplemented with 10% FBS penicillin
and streptomycin) was then added. After several days,
outgrowth of spindle shaped cells was observed. Tissue
debris and non-adherent cells were removed and medium
changed between day 2–4. For tissues (n = 14) weighing
more than 0.5 gram (TB71 - TB148) the tissue was
minced as described above and then enzymatically disso-
ciated in tissue digestion buffer containing collagenase I
(Worthington), hyaluronidase (Sigma), Collagenase IV
(Worthington) at 1 mg/ml of each enzyme in DMEM/
F12 medium in a volume of 1:5 ratio of tumor to buffer
(wt/vol) on a gyrating platform at 37o C for 30 min. The
digestion was quenched by addition of fibroblast growth
medium and filtered through a 70 μm cell strainer. Cells
were pelleted at 1500 rpm for 10 min. Tissue debris and
non-adherent cells were removed during medium change
between day 2 or 4. By 10 – 14 days, near confluent ad-
herent spindle shaped cells were harvested using 0.25%
trypsin in versene, washed and replated in fresh fibroblast
growth medium. Medium was changed every 4 – 7 days.
CAFs from early passages (passage 2–3) were harvested
and the cell pellet was stored in RNA later (Applied
Biosystems) at −80°C until RNA was isolated.
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RNA purification was carried out using TRI ReagentW
(Molecular Research Center) according to manufacturer’s
recommendations. RNA quality was determined using
the Bioanalyzer (Agilent). Only samples with RIN num-
bers > 7.5 were used for further studies. Equal amounts
(400 ng) of total RNA was amplified as recommended
by Illumina and hybridized to the HumanHT-12 v4
human whole genome bead arrays. Illumina BeadStudio
v.3.0 software was used to export expression levels and
detect p-values for each probe of each sample. Quality
control of each array was performed using median
Spearman correlation computed against all other arrays.
Arrays whose median correlation differed from the glo-
bal correlation by more than 8 absolute deviations were
marked as outliers and not used for further analysis
(resulting in the removal of one TNBC sample, TB147
(Table 1)). The remaining 19 arrays were then quantile-
normalized between each other and filtered to remove
non-informative probes (probes with a detection p-
value > 0.05 in all samples). Between-batch normalization
was performed using Distance Weighted Discrimination
(DWD) approach [19] using 4 samples replicated in the
2 microarray batches. Average expression between repli-
cates was used for data analysis. The data was submitted
to GEO database (http://www.ncbi.nlm.nih.gov/geo/) and
available by using accession number GSE37614.Table 1 List of samples used in gene expression analyses
Subtype Patient ID b1 b2 Set












TB98 x x testing
TB120 x
Her2+ TB76 x training
TB117 x x
TB136 x
TB122 x x testing
TB129 x
Her2+/ER+ TB148 x testing
List of samples divided into two batches (b1 and b2) including two samples
from each subtype as an independent validation (testing) set as indicated.Flow cytometry analysis
1Adherent early passage CAFs were harvested with
0.05% trypsin/versene, washed in standard FACS buf-
fer containing (5 ul/test) Fc blocking antibodies as
recommended by the manufacture (Biolegend), and
stained with the following directly conjugated antibodies
for the evaluation of surface markers by flow cytometry
analyses:
EpCAM: PE anti-human CD326 clone 9C4 (Biolegend)
used at 1ug/ml; PE-F19: mouse anti-human FAPα mono-
clonal antibody (clone F19), used at 1/10 dilution, was
purified from serum-free hybridoma supernatant as
described [20,21]; CD45: APC mouse anti-human CD45
(BD Pharmingen) used at 20ul/test according to manu-
facturer's recommendation; CD31: APC anti-human
CD31 clone WM59 (eBioscience) used at 5ug/ml.
Independent validation
We randomly selected two samples from each Her2+, ER+
and TNBC subtype as an independent validation set (test-
ing set, Table 1). One sample which was unique in its sub-
type classification in that the CAF was derived from a
Her2+ and ER+breast cancer (TB148, Additional file 1:
Table S1) was also added to the testing set in order to
show how it would be classified based only on its gene ex-
pression profile. The training set used to select the genes
that distinguish the 3 CAF subtypes included 3 Her2+, 5
ER+ and 4 TNBC samples was analyzed with one way
ANOVA to identify a list of significant genes with p-
value < 0.05 used as a significance threshold. Expression
patterns of the significant genes were used for Principal
Component Analysis. Projection of training and testing set
samples on the first two principal components was used to
visualize relationship between samples.
Differentially expressed genes
After the validation, a final list of significant genes differ-
entially expressed between three classes of samples
(Her2+, ER+ and TNBC) was determined by using one
way ANOVA on the full set of samples, except for the
one Her2+/ER + sample (TB148). False discovery rate
(FDR) was determined according to published protocol
[22]. Significance for genes between each pair of groups
was determined by Tukey post-hoc test. P-value <0.05
was set as a significance threshold.
Gene enrichment analysis
Identification of biological functions and pathways overre-
presented in any gene list was done using DAVID [23] and
Ingenuity Pathway Analysis (IPA) software (Ingenuity Sys-
tems, Redwood City, CA). DAVID results were restricted
to gene ontology (GO) terms, KEGG, and BIOCARTA
pathways and Swiss-Prot keyword enrichments and fil-
tered to satisfy FDR <5% and fold enrichment >2 criteria.
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Hochberg corrected for multiple testing p-value < 0.05.
Heatmap
Heatmap was generated for a list of the 44 significant
genes (with a fold change > 2) that distinguish Her2+
CAFs from both ER+ and TNBC derived CAFs. Genes
were hierarchically clustered using Spearman correlation
distance and complete linkage. Heatmap color intensities
were proportional to a value calculated as a ratio between
the gene expression in a single sample and the geometric
mean expression of the gene across all samples.
qPCR validation
Expression of six genes, ITGA3, ITGA5, OXTR, WNT5B,
BCAR1 and FZD1, as well as 3 endogenous controls (ec)
RPL19, TBP and UBA5 were assessed by qRT-PCR in tripli-
cates. Median Ct values for each gene were used for ΔΔCt
analysis, where ΔCt was calculated against average Ct of
the three endogenous controls and ΔΔCt calculated as dif-
ference between average ΔCt values of compared groups.
Final fold change between a pair of groups was calculated
as 2ΔΔCt. Significance of the difference between two groups
was tested by two-tail t-test on ΔCt values. For comparison
with expression values from microarrays, corrected for
loading bias absolute expression values E for each gene G
were calculated as follows: E=AEG/(AEec/avg(AEec)),
where absolute expression AEG=2
40-Ct, AEec is an average
AE between three endogenous controls and avg(AEec) is an
average of AEec taken across all samples. Expression values
were then normalized for microarray and qRT-PCR data
separately over three group average absolute expression
values.
Transwell migration assay
The migration properties of T47D (ATCC), a breast can-
cer cell line, known to have low migratory properties
[24], was evaluated in the presence or absence of CAFs
derived from ER, TNBC, and Her2+ breast cancer using
a transwell assay. CAFs (1×104 cells) from each of the
three subtypes were seeded in 100 μl of DMEM contain-
ing 1% serum medium in the lower well of a Transwell
chamber (Costar, Inc.) with 8 μm pore size polycarbonate
filters and left to attach for 90mins. As control, medium
containing no CAFs was placed in the lower well. T47D
(1×104 cells) were then seeded onto the upper chamber
in 1% serum medium. Transwell chambers were incu-
bated for 48 hours at 37°C and 5% CO2. Membranes
were stained with DAPI (Invitrogen) for 15 min, rinsed
with PBS and fixed with 10% buffered formalin (Fisher
Scientific, SF100-20) for 15 min before imaging. The
number of T47D cells that migrated onto the underside
of the membrane was counted in 5 fields using a Nikon
TE2000 inverted microscope at 10× magnification andplotted. Statistical evaluation was performed using Graph
Pad Prism (GraphPad Software, Inc.).
Results
Isolation of CAFs from fresh human breast cancer
samples
The clinical characteristics of the study cohort are sum-
marized in Table 2. Detailed clinical characteristics of each
tumor are provided in Additional file 1: Table S1. No sig-
nificant differences were noted among the three subgroups,
except for tumor grade (Table 2). The morphology of CAFs
isolated from the 3 different breast cancer subtypes was
similar (Figure 1). Further phenotypic characterization
using flow cytometry analysis demonstrated that >95% of
these cells expressed fibroblast activation protein (FAP), a
previously identified marker of cancer associated fibro-
blasts [25-28]. Moreover, >99% of the cells were negative
for the epithelial cell adhesion molecule (EpCAM), a breast
cancer epithelial cell surface marker [12]; CD31, also
known as platelet endothelial cell adhesion molecule
(PECAM-1), an endothelial cell marker, and CD45, a pan-
leukocyte marker (Figure 2, lower panel). Moreover, these
CAFs uniformly expressed vimentin and collagen by
immunohistochemistry (data not shown).
Gene expression profile analyses of CAFs derived from
TNBC, ER + and Her2+ breast cancer
RNA isolated from the early passage CAFs were assayed
for gene expression and randomly assigned to two sam-
ple sets, namely, training and testing sets (Table 1) to
perform independent validation. Using one-way ANOVA
on the training set (4 TNBC samples, 5 ER + samples
and 3 Her2+ samples)), we identified 782 genes that
were differentially expressed between TNBC, ER + and
Her2+ samples (p-value < 0.05). In order to visualize the
relationships between the sample types, we performed
unsupervised Principal Component Analysis using the
782 significant genes (Figure 2A). This type of plot
reflects the similarities and differences between all sam-
ples in relation to the 782 significant genes. It should be
noted that the first principal component plotted on the
X axis accounts for 49% of the variation in the data and
indicates that there are significant differences between
the CAFs derived from the Her2+ cancers and both the
TNBC and ER+ breast cancers, as these samples are
equally separated from the Her2+ samples along the X
axis. The second principal component plotted on the Y
axis accounts for only 14% of the gene expression vari-
ation between all samples. It captures putative differ-
ences between the ER+ and TNBC samples and
indicates that the expression profiles are much more
similar between these two subtypes.
We then determined whether the training set princi-
pal components could also distinguish the new Her2+,
Table 2 Clinical characteristics of breast cancer study cohort
Overall TNBC ER+ Her2+ p-values
TNBC vs. ER+ TNBC vs. Her2+ ER+ vs. Her2+
n 20 7 7 6
Age at diagnosis mean ± standard deviation 52 ± 16 47 ± 14 59 ± 18 49 ± 16 0.21 0.83 0.33
Ethnicity
Caucasian 10 3 5 2 0.59 1 0.56
African American 9 4 2 3
Asian 1 0 0 1
Invasive carcinoma
histology
ductal 14 7 3 6 0.07 1 0.19
lobular 6 0 4 0
Tumor size (cm) mean ± standard deviation 4.8 ± 4.2 3.0 ± 1.1 4.9 ± 2.5 5.7 ± 7.4 0.06 0.35 0.81
T1 <2 cm 4 1 1 2
T2 2.1 - 5 cm 10 6 2 2
T3 >5 cm 6 0 4 2
Tumor grade
I 0 0 0 0
II 3 1 3 0 0.03 1 0.03
III 11 6 0 4
not assessed 6 0 4 2
No. of involved axilla node(s)
mean ± standard deviation
5.5 ± 7.8 4.1 ± 8.6 6.4 ± 8.4 6.0 ± 7.0 0.10 0.56 0.52
0 8 5 1 2
1-3 4 0 4 0
4-9 3 1 0 1
>9 4 1 2 2
not assessed 1 0 0 1
Receptor status
ER+ 8 0 7 1
PR+ 7 0 7 0
Her2+ 6 0 0 6
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tial observations. Figure 2A shows the separation of the
12 samples representing the 3 original sample types in
the training set that we used to select the significant
genes that defined this separation. Figure 2B confirms
these genes also identify the subtype differences in new
samples analyzed as an independent validation set and
included two new Her2+ samples and t two new ER +
and two new TNBC samples. The new Her2+ samples
clearly cluster with the Her2+ samples in the training
set while the new ER + and TNBC samples once again
cluster with the ER + and TNBC training set samples.
Although the ER + and TNBC derived CAFs appear to
self segregate along the 2nd principal component in the
training set (Figure 2A), no significant differences in
gene expression were detected between the ER + and
TNBC CAFs in the testing set (Figure 2B). Thisindicates that there is a high degree of gene expression
similarity in the CAFs associated with the ER + and
TNBC cancer subtypes.
It should also be noted that new sample TB148, which
is both Her2+ and ER+, co-segregates with the Her2+
samples which were all ER- (Figure 2B), indicating the
presence of a gene expression profile more similar to the
Her2+ CAFs and not the ER +CAF sample group. This
indicates a dominance of Her2+ CAF gene expression
signature over ER +CAF signature.
We also combined the expression data for all samples
(except for the Her2+/ER+TB148) to take advantage of
the larger sample size and ran one way ANOVA to define
a final list of significant genes differentially expressed be-
tween Her2+, ER+and TNBC in the larger data set. We
found 1829 differentially expressed genes with p-value <
0.05 and estimated false discovery rate of 28%. When the
Figure 1 Characterization of CAFs from breast cancer subtypes by morphology (light microscopy) and flow cytometry analysis. Top
panel, 20x magnification light microscopy pictographs of a) ER+; b) TNBC and c) Her2+ breast cancer derived CAFs; Lower panel, histograms
(dark solid line) depicting CAFs staining for (left to right): EpCAM, FAP, CD45, and CD31; light grey lines depict histogram of CAFs staining with
isotype control antibodies.
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reassessed using Principal Component Analysis with
the new gene set, we found the same cancer subtype
specific differences as demonstrated on training sub-
set (Figure 2A).
The number of significant genes identified by pair-
wise comparisons (Tukey post-hoc test) between the
three classes of patient samples, i.e. Her2+ vs ER+, Her2+
vs. TNBC and ER+ vs TNBC samples, are presented in
the Venn diagram in Figure 3. These results quantify the
visual interpretation of Principal Component Analysis
demonstrating that while 1,800 genes were significantly
differentially expressed between Her2+ and either ER+ or
TNBC, only 118 genes were significantly different between
ER+ and TNBC derived CAFs. Further studies with
increased number of samples for ER+ and TNBC derived
CAFs will be required to identify genes that can discrimi-
nate those 2 classes, if they exist. A gene expression heat
map for the 44 most changed unique genes (fold change>2)
which were common to the Her2+ vs ER+and Her2 +
vs TNBC comparisons are shown in Figure 4.
Functions and pathways over-represented in the list of
genes that distinguish Her2+ from ER+ and TNBC CAFs
We compared the two significant gene lists for Her2+ vs
ER+and Her2+ vs TNBC to identify functions or pathways
that might be over-represented among the differentially
expressed genes. Results with DAVID software analyses[23] are shown in Additional file 2: Table S2 for the Her2+
vs ER+1253 significant genes, and in Additional file 3:
Table S3 for Her2+ vs TNBC 1035 significant genes.
Enrichment of nine functional categories associated with
cytoskeleton and extracellular matrix were found to be
significant in both comparisons.
Ingenuity pathway analysis was done for a list of
615 genes common between Her2+ vs ER + and Her2+
vs. TNBC comparisons. A list of significantly enriched
canonical pathways is presented in Table 3. Pathways
involving extracellular matrix/integrin signaling were
found to be significantly up-regulated in CAFs derived
from Her2+ cancer, further supporting the DAVID
results. It should be noted that 92% (61 of the 66 unique)
of the genes associated with the ingenuity pathways are
upregulated in Her2+ supporting the hypothesis that
those pathways are more active in CAFs derived from
Her2+ breast cancer as compared to those derived from
the ER+ and TNBC breast cancers.
Q-RT-PCR validation of individual gene expression data in
CAFs
To confirm differential gene expression levels in the
three breast cancer subtypes, Her2+, ER + and TNBC,
we selected 6 genes (ITGA3, ITGA5, OXTR, WNT5B,
BCAR1, FZD1) with significantly different levels of ex-
pression based on our microarray studies and validated






























































Her2+ / E R +
A B
Figure 2 Relationship between Her2+, ER + and TNBC classes of samples visualized by Principal Component Analysis (PCA) on the
training set samples using expression of genes differentially expressed between the three classes. A. Training set samples B. Projection of
testing set samples on the first and second principal components derived from the training set. White square in dark grey diamond indicates
tested sample with double diagnosis Her2+/ER+.
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6.9 fold. Five of the 6 genes that were found to be
expressed at higher levels in the Her2+ samples were
also significantly different in the Her2+/ER + qRT-PCR
comparison; and 4 of those 5 genes that were signifi-
cantly different in the Her2+/TNBC array comparison
were also significantly different by qRT-PCR comparison
(Figure 5 and Additional file 4: Table S4). Expression
ratios by qRT-PCR were highly consistent with array
values and overall somewhat higher by qRT-PCR as
expected. One gene, FZD1, which was expressed at
lower levels in CAFs derived from Her2+ breast cancer
by array analyses, was also significantly lower by qRT-
PCR in the Her2/TNBC comparison but was not signifi-









Figure 3 Venn diagram for genes common between three pair-wise calthough fold change values were similar by qRT-PCR
(TNBC/ER+= 1.33 for microarrays and 1.39 for qPCR).
Her2 CAFs enhanced the migratory phenotype of breast
cancer cells in vitro
To explore whether CAFs derived from various breast
cancer subtypes can differentially enhance the migratory
phenotype of breast cancer cells, we performed in vitro
transwell assays comparing the migration of breast cancer
cells cultured in the presence or absence of CAFs isolated
from ER+, Her2+ and TNBC. The number of migrated
T47 cells onto the membrane surface that was facing the
lower chamber was counted. Results were analyzed by un-
paired Kruskal-Wallis test. The level of statistical signifi-
































































































































































































Figure 4 Heat map of expression for 44 genes with the greatest differences between Her2+ vs. ER+ and Her2+ vs. TNBC comparisons.
FC= fold change from geometrical mean of expression across all samples.
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breast cancer significantly enhanced the migration of
T47D (Figure 6).
Discussion
Robust evidence is now available that underscores the
role of CAFs in tumor progression [8,28-33]. Previous
gene expression profile analyses comparing CAFs and
fibroblasts derived from matched normal adjacent breasttissues have demonstrated significant differences between
the CAF and their normal counterparts but, to the best of
our knowledge, no prior studies have addressed whether
CAFs derived from various breast cancer subtypes harbor
subtype specific gene expression signatures. In this study
we demonstrate for the first time that CAFs from several
breast cancer subtypes exhibit subtype-specific gene ex-
pression profiles. Specifically, we show that the gene ex-
pression profile of CAFs derived from Her2+ breast
Table 3 Canonical pathways upregulated in Her2+ compared to ER+ and TNBC samples
Enriched ingenuity
canonical pathways
pval # of genes Genes
P L " #
Actin Cytoskeleton Signaling 0.0002 226 20 20 0 PFN1", MYL6", CFL1", ARPC5L", CSK", HRAS", ITGA5", IQGAP1", ITGA3",
BCAR1", ACTG1", MYL9", MYL12A", PIP5K1C", ARPC2", RHOA", MYH9",
VCL", ACTN1", MSN"
Integrin Signaling 0.0008 205 18 18 0 MAP3K11", RHOC", ARPC5L", ILK", HRAS", PLCG1", ITGA5", TNK2",




0.001 87 11 11 0 MYL9", MYL12A", PFN1", CFL1", MYL6", ARPC5L", PIP5K1C", RHOC",
ARPC2", RHOA", ARHGDIA"
Rac Signaling 0.002 117 12 12 0 RELA", MAP3K11", CFL1", ARPC5L", PIP5K1C", ARPC2", RHOA", ITGA5",
HRAS", SH3RF1", ITGA3", IQGAP1"
Cdc42 Signaling 0.003 142 13 13 0 MPRIP", MAP3K11", CFL1", MYL6", ARPC5L", ITGA5", TNK2", ITGA3",
IQGAP1", HLA-F", MYL9", MYL12A", ARPC2"
ILK Signaling 0.005 182 15 14 1 RELA", CFL1", MYL6", RHOC", ILK", ACTG1", MYC#, NCK2", MYL9",
TGFB1I1", PPP2R1A", FLNA", RHOA", MYH9", ACTN1"
RhoA Signaling 0.006 107 11 11 0 MYL9", MYL12A", PFN1", CFL1", MYL6", ARPC5L", PIP5K1C", ARPC2",
RHOA", ACTG1", MSN"




0.010 159 13 13 0 MAP3K11", RHOC", TUBB2A", ILK", HRAS", ITGA3", IQGAP1", BCAR1",
ACTG1", TUBB6", SORBS1", RHOA", ACTN1"
Cardiac Hypertrophy Signaling 0.010 228 16 14 1 MAP3K11", CALM1", MYL6", RHOC", PLCG1", HRAS", PPP3CC", EIF2B2",
MYL9", GNB1", PLCD3#, MYL12A", PLCB4", RHOA", MAPKAPK2", HSPB1"
Phospholipase C Signaling 0.01 243 16 14 0 RELA", MYL6", CALM1", RHOC", PLCG1", ITGA5", PPP1R14A", HRAS",
ARHGEF17", PPP3CC", ITGA3", MYL9", GNB1", PLCB4", MYL12A", RHOA"
Protein Kinase A Signaling 0.01 306 19 13 3 RELA", YWHAH", MYL6", CALM1", PPP1R14A", PLCG1", PPP1R11",
PPP3CC", MYL9", GNB1", PLCD3#, MYL12A", PLCB4", NFKBIA#,
PDE7B#, FLNA", RHOA", NFKBIB", PDE6D"
FAK Signaling 0.01 98 9 9 0 CSK", PLCG1", ITGA5", HRAS", VCL", ITGA3", TNS1", BCAR1", ACTG1"
fMLP Signaling in Neutrophils 0.01 117 10 6 0 GNB1", RELA", PLCB4", NFKBIA#, CALM1", ARPC5L", ARPC2", HRAS",
PPP3CC", NFKBIB"
Axonal Guidance Signaling 0.04 422 21 21 0 KLC1", PFN1", GLI2", PLXNA3", MYL6", CFL1", ARPC5L", TUBB2A",
HRAS", TGA5", PPP3CC", ITGA3", BCAR1", NCK2", MYL9", GNB1",
PLCB4", MYL12A", TUBB6", ARPC2", RHOA"
Neuregulin Signaling 0.04 95 8 6 2 MYC#, PICK1", PLCG1", ITGA5", HBEGF", HRAS", ITGA3", STAT5B#
PAK Signaling 0.05 104 8 8 0 NCK2", MYL9", MYL12A", CFL1", MYL6", ITGA5", HRAS", ITGA3"
Virus Entry via Endocytic
Pathways
0.05 92 8 8 0 AP2M1", FLNA", PLCG1", ITGA5", HRAS", ITGA3", ACTG1", DNM2"
pval=Benjamini-Hochberg corrected p-value, P = total number of genes known to be involved in the pathway, L = number of genes from the pathway that were
also in the list of significant genes. "=number of genes significantly upregulated in Her2+, #= number of genes significantly downregulated in Her2+. The 18
significantly enriched pathways share 66 unique genes with 61 of those upregulated in Her2+ compared to ER + and TNBC.
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ER+or TNBC breast cancers.
Heterogeneity among fibroblasts has been described in
various organ sites including lung, skin, sclera and orbit
[34]. Furthermore, Sugimoto and coworkers demon-
strated that the expression of various fibroblast markers
are heterogeneous within the tumor stroma in mouse
breast and pancreatic tumor models using immunohisto-
chemical analyses [35]. Several studies have generated
gene expression profiles from breast cancer-associated
fibroblasts but none of these studies have stratified their
results based on tumor subtypes. Work by Allinen andcoworkers evaluated gene expression profiles of breast
cancer stromal cells which were isolated by negatively
selecting out epithelial cells, lymphocytes and endothelial
cells [12]. Work described by Singer et al. compared gene
expression profiles of stromal fibroblasts derived from 10
invasive breast cancers with stromal fibroblasts derived
from normal breast tissues of 10 women undergoing
breast reduction surgery [16]. Their results demonstrated
increased expression of tumor promotion-associated
genes in the pooled CAFs. Work by Bauer et al. (2010)
evaluated gene expression profiles of fibroblasts derived











































































































































Figure 5 qRT-PCR validation. qPCR was used to validate microarray results for 6 genes found to be significantly different in either Her2+ vs ER+,
Her2+ vs TNBC or ER+ vs TNBC comparison in microarrays data. Expression for arrays and qPCR were normalized separately over average value across
absolute expression for Her2+, ER+ and TNBC groups. Error bars represent standard error of mean for the group.
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CAFs and normal fibroblasts, specifically in genes
related to paracrine or intracellular signaling, transcrip-
tional regulation, extracellular matrix and cell adhesion/
migration. However, all of the above studies were not
designed to test subtype specific differences in CAFs
due to these studies’ relatively small sample size. In
addition, when tumor subtype data were reported, the
less common breast cancer subtypes, i.e., Her2+ or TNBC
cancer, were underrepresented.
Our results showed that CAFs derived from Her2+ breast
cancers significantly up-regulated pathways associated withactin cytoskeleton and integrin signaling (Table 3). Integrins
mediate cell attachment with extracellular matrix (ECM) to
provide traction necessary for cell motility and invasion.
These upregulated signaling pathways may have contribu-
ted to the elevated migratory phenotype of breast cancer
cells (T47D) in our in vitro transwell assays (Figure 6).
The extracellular matrix and integrins collaborate to
regulate gene expression associated with cell growth, dif-
ferentiation and survival; all of which are deregulated
during cancer progression and metastasis. A recent
study using a three-dimensional squamous cell car-
cinoma (SCC)/fibroblast co-culture model elegantly
Figure 6 CAFs derived from Her2+ breast cancer significantly enhances the migration of T47D cells in vitro. In vitro transwell assays
comparing T47D migration in the absence (orange) or presence of CAFs isolated from ER (black), Her2 (blue) and TNBC (green) primary human
breast cancer tumors were performed. Each experiment was performed in duplicates using CAFs derived from at least two different patients. One
CAF cell line of each subtype was tested in 2 independent experiments (open vs. closed circles). The second CAF cell line of each subtype
(squares) was tested in duplicate in one independent experiment, for a total of 6 tests. Lines show mean± SEM.
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rin α5 and Rho, in promoting a fibroblast-led collective
invasion of SCC cells into the extracellular matrix [17].
Interestingly, all three genes were significantly up-
regulated in CAFs derived from Her2+ breast cancer
with integrin signaling as the second most enriched
pathway (Table 3). Moreover, many of the genes and
pathways downstream of integrin signaling are also sig-
nificantly upregulated in Her2+ CAFs. These include
focal adhesion kinase (FAK), Rac and Rho signaling
pathways as well as several members of the mitogen-
activated protein kinases (MAPKs), further underscor-
ing the importance of integrin signaling in CAF. In
addition to the well-established role of integrins in mi-
gration and invasion, integrins can also regulate cell
proliferation, including mammary gland proliferation
[36] through integrin-linked kinase (ILK) [37], which
was also noted to be significantly upregulated in HER2+
derived CAFs. These characteristic differences in CAFs
derived from Her2+ breast cancer may contribute to the
aggressiveness of this particular breast cancer subtype
which is known to have an increased propensity for
local and distant recurrence [3]. In addition, the sites of
distant metastasis appear to differ according to breast
cancer subtype with Her2+ breast cancer having a
higher rate of brain, liver, and lung metastases than ER +
breast cancer [38]. The role of CAF in contributing to a
subtype-specific trophism for the various distant meta-
static sites is unknown.
Gene expression profile differences between CAFs
derived from ER+ and TNBC breast cancer were lesspronounced and we were unable to confirm them with
independent validation set using the limited sample
numbers (Figure 2B). While it is possible that true differ-
ences may exist among these two subtypes, a larger
number of samples would be required to find those
differences with an acceptable false discovery rate.
Conclusions
Our results show that subtype specific changes exist in
CAFs derived from breast cancer. In the case of Her2+
breast cancer, a more aggressive breast cancer subtype with
known increased risk of local and distant recurrence, CAFs
may augment the invasive properties of the tumor cells via
pathways associated with cytoskeleton and integrin signal-
ing. Our findings also provided molecular evidence sup-
porting a recently proposed tumor-stroma co-evolution
hypothesis which suggested that the tumor microenviron-
ment, e.g. CAFs, may adopt specific changes to optimize
the survival/propagation of a specific tumor cell type [5].
Whether these programmatic differences in CAFs result
from epigenetic changes or whether these differences
are due to heterogeneity within the CAF population,
i.e. proportion of resident fibroblasts vs. recruited fibro-
blasts, or fibroblasts derived from epithelial mesenchymal
transition are unknown. In addition, whether CAFs con-
tribute to tumor progression in a subtype specific manner
is unknown. How CAFs and other components of the
tumor microenvironment drive or are being driven by
the tumor cells to promote the propagation and mainten-
ance of a specific tumor subtype will be the subject
of future work.
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Additional file 1: Table S1. Clinical Characteristics of Study Cohort.
Additional file 2: Table S2. Annotation categories enriched in the list
of genes significantly differentially expressed in Her2+ compared to ER+
samples as determined by DAVID software. Cat=category, Term=enriched
annotation term, Enr=enrichment, TN=enrichment of the Term in Her2+
vs. TNBC comparison, Sens=sensitivity in a form K/N(P%), where
K=number of genes in the list, N=total known number of genes, P=K/N
in percentage. P=Fisher exact p-value for enrichment, FDR=false
discovery rate, " = number of genes upregulated in Her2+, # = number
of genes downregulated in Her2+, SP.KW = SwissProt keyword,
KEGG=KEGG pathway, GO=gene ontology, BP=biological process,
FM=molecular function, CC=cellular component.
Additional file 3: Table S3. Annotation categories enriched in the list
of genes significantly differentially expressed in Her2+ compared to TNBC
samples as determined by DAVID software. Cat=category, Term=enriched
annotation term, Enr=enrichment, ER+=enrichment of the Term in Her2+
vs. ER+ comparison, Sens=sensitivity in a form K/N(P%), where K=number
of genes in the list, N=total known number of genes, P=K/N in
percentage. P=Fisher exact p-value for enrichment, FDR=false discovery
rate, " = number of genes upregulated in Her2+, # = number of genes
downregulated in Her2+, SP.KW = SwissProt keyword, GO=gene
ontology, BP=biological process, FM=molecular function, CC=cellular
component.
Additional file 4: Table S4. Fold changes and p-values obtained by
qRT-PCR validation experiment for 6 genes found to be significantly
different in either Her2+ vs ER+, Her2+ vs TNBC or ER+ vs TNBC
comparison in microarrays data. FC=fold change, P=significance by
t-test. Visual comparison of expression values between microarrays and
qRT-PCR are presented in Figure 6.
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